View Older Stories View More Recent Stories

Oct 18, 2017 07:01AM Alnylam Pharma (ALNY), Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Disease
Oct 18, 2017 07:01AM Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases
Sep 26, 2017 08:01AM Alnylam Pharma (ALNY) Commences Phase 2 Clinical Study of Cemdisiran (ALN-CC5)
Sep 26, 2017 08:00AM Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
Sep 25, 2017 08:00AM Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform at 13th
Sep 20, 2017 07:02AM Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
Sep 20, 2017 07:01AM Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary Endpoints
Sep 20, 2017 07:00AM Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 07:00AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 06:58AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 7, 2017 07:02AM Alnylam Pharma (ALNY) Reports Fatal Thrombotic Event in Study of Fitusiran, Suspends Dosing
Sep 7, 2017 07:00AM Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs
Sep 5, 2017 04:00PM Alnylam to Webcast Presentation at 15th Annual Morgan Stanley Global Healthcare Conference
Aug 28, 2017 07:04AM Medicines Co. (MDCO), Alnylam (ALNY) Announces New, Positive Data from ORION-1 Phase II Study of Inclisiran
Aug 28, 2017 07:00AM New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
Aug 9, 2017 04:00PM Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity
Aug 1, 2017 04:00PM Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results
Jul 27, 2017 08:00AM Alnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series
Jul 10, 2017 09:33AM Sanofi Genzyme and Alnylam (ANLY) Announces Positive phase 2 Results in Hemophilia A and B
Jul 10, 2017 09:31AM Alnylam Pharma (ALNY) & Sanofi (SNY) Genzyme Announce Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran
Jul 10, 2017 09:30AM Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
Jul 10, 2017 09:30AM Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without I
Jul 7, 2017 07:32AM Alnylam Pharma (ALNY), Sanofi (SNY) Initiate Phase 3 Program for Fitusiran for Hemophilia A and B
Jul 7, 2017 07:30AM Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors
Jun 26, 2017 04:02PM Alnylam (ALNY) Sanofi (SNY) Genzyme to Present New Clinical Trial Results at ISTH
Jun 26, 2017 04:01PM Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress
Jun 26, 2017 05:46AM Alnylam Pharma (ALNY) Announced New Positive Clinical Results for Givosiran (ALN-AS1)
Jun 26, 2017 05:45AM Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Jun 19, 2017 04:00PM Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term
Jun 12, 2017 07:32AM Alnylam Pharma (ALNY) Reports Expansion of Patent Portfolio with New Allowances from United States Patent & Trademark Office
Jun 12, 2017 07:30AM Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office
Jun 7, 2017 08:30AM Alnylam Expands Third Annual “Helping Hands” Community Service Day Globally to Benefit 18 Organizations
May 31, 2017 07:32AM Alnylam Pharma (ALNY) Granted FDA Breakthrough Designation for Givosiran (ALN-AS1)
May 31, 2017 07:30AM FDA Grants Breakthrough Therapy Designation for Alnylam’s Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria
May 30, 2017 04:00PM Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference
May 12, 2017 04:00PM Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer
May 10, 2017 04:00PM Alnylam to Webcast Presentations at Upcoming May Investor Conferences
May 9, 2017 08:03AM Alnylam Pharma (ALNY) Names Manmeet S. Soni as CFO
May 9, 2017 08:00AM Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders
May 5, 2017 08:00AM Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
Apr 27, 2017 04:00PM Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results
Apr 26, 2017 08:14AM Alnylam Pharma (ALNY) Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran to Treat hATTR
Apr 26, 2017 08:00AM Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Apr 26, 2017 07:05AM Medicines Company (MDCO), Alnylam (ALNY) Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
Apr 26, 2017 07:00AM The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
Nov 14, 2016 09:24AM Pre-Open Stock Movers 11/14: (CRBP) (HAR) (DGII) (MENT) Higher; (DVAX) (HEAR) (ACM) Lower (more...)
Oct 6, 2016 12:57PM Unusual 11 Mid-Day Movers 10/6: (GNK) (AUPH) (GTWN) Higher; (ALNY) (INVT) (TWTR) Lower
Oct 6, 2016 09:22AM Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
Oct 3, 2016 09:00AM Alnylam Commemorates 10th Anniversary of the Nobel Prize in Physiology or Medicine Awarded for the Discovery of RNAi
Aug 31, 2015 05:20PM Market Wrap: Crude Staves-Off Loss for August; Apple, Cisco Enter Partnership; Twitter Gains on Upgrade
View More Recent Stories View Older Stories